Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3203 - Correlation between alternative endpoints and overall survival in metastatic colorectal cancer patients eligible to a maintenance strategy


08 Oct 2016


Poster Display


Anthony Turpin


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


A. Turpin1, S. Paget-Bailly2, A. Ploquin1, A. Hollebecque3, S. Dominguez4, F. Bonnetain2, F. El Hajbi5, M. Hebbar1

Author affiliations

  • 1 Oncologie Médicale, C.H.U. Claude Huriez, 59000 - Lille/FR
  • 2 Unité De Méthodologie Et Qualité De Vie En Cancérologie (ea3181), CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 3 Department Of Medicine Ditep, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 4 Oncologie Médicale, Hopital Saint Vincent, 59800 - Lille/FR
  • 5 Dept De Cancerologie Digestive, Centre Oscar Lambret, 59020 - Lille/FR


Abstract 3203


In this study, our first aim was to assess the relation between different intermediate criteria and overall survival (OS) in patients treated for a metastatic colorectal cancer (mCRC) receiving a first-line chemotherapy associated with bevacizumab.


We collected retrospective data from patients with mCRC treated with 1st-line chemotherapy (generally FOLFIRI-FOLFOX regimen) plus bevacizumab between January 2006 and December 2012. We assessed the following time to event endpoints: OS; progression free survival (PFS); duration of disease control (DDC), the sum of the periods in which the disease did not progress, and the time to failure of strategy (TFS), the whole period before the introduction of second-line treatment. Linear correlation and linear regression models were used to study relations between OS and TFS, and OS and DDC, respectively. Prentice criteria for surrogacy were investigated.


We included 216 patients from 6 centers. 91 (42%) patients received a maintenance strategy. With a median follow-up of 57.6 (43.6-94.0) months, median OS was 24.5 (21.3-29.7) months, median PFS was 8.9 (8.4-9.7) months, median DDC was 11.0 (9.8-12.4) months, and median TFS was 11.1 (10.0-13.0) months. Pearson coefficient (coeff) was 0.79 (CI 95% 0.73-0.83) and determination coeff was 0.62, suggesting of a satisfactory correlation between OS and DDC. Similarly, the correlation between OS and TFS was rather satisfactory with a Pearson coeff at 0.79 (CI 95% 0.73-0.84) and a determination coeff at 0.63. Linear regression analysis showed a significant association between OS and DDC, and between OS and TFS, respectively. These relationships can be modeled by the formulas: cube root (SG) = 0.9547 + 0,8286 cubic root (DDC) and cubic root (SG)= 0.9655 +0,8186 cubic root (TFS). Considering resection of metastases as the treatment, Prentice criteria were verified for both TFS and DDC.


DDC and TFS were correlated to OS and Prentice criteria were validated for both endpoints. This makes them relevant as intermediate criteria, in the setting of patients with mCRC treated with 1st-line bevacizumab-based regimen.

Clinical trial identification

Legal entity responsible for the study

CHRU de Lille


CHRU de Lille


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings